---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-048502"
form_type: "8-K"
ticker: "DERM"
cik: "0001867066"
company_name: "Journey Medical Corp"
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T10:29:09.411088+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Journey Medical reports Q1 net loss narrows to $4.1M; Emrosi launch underway

## Summary
- Net loss $4.1M ($0.18/sh) vs $10.4M loss ($0.53/sh) in Q1 2024.
- Revenue $13.1M, flat YoY; includes $2.1M from Emrosi launch.
- Gross margin improved to 64% from 54% YoY; R&D costs nil vs $7.9M.
- Cash $21.1M at March 31, 2025 (vs $20.3M at Dec 31, 2024).
- Emrosi commercial launch started April 7; Phase 3 results published in JAMA Dermatology.

## SEC filing metadata
- accession: 0001104659-25-048502
- form_type: 8-K
- ticker: DERM
- cik: 0001867066
- company_name: Journey Medical Corp
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867066/000110465925048502/0001104659-25-048502-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867066/000110465925048502/tm2514979d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-048502
- JSON: https://secwatch.observer/filing/0001104659-25-048502.json
- Plain text: https://secwatch.observer/filing/0001104659-25-048502.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.